 Karen Christopher
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract Extraction | 10 | 2025 | 120 | 5.000 |
Why?
| | Cataract | 11 | 2023 | 238 | 4.900 |
Why?
| | Keratomileusis, Laser In Situ | 4 | 2024 | 20 | 2.780 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 49 | 2.760 |
Why?
| | Myopia | 5 | 2024 | 59 | 2.720 |
Why?
| | Refraction, Ocular | 5 | 2024 | 47 | 2.400 |
Why?
| | Visual Acuity | 9 | 2025 | 491 | 2.360 |
Why?
| | Lasers, Excimer | 4 | 2024 | 30 | 2.240 |
Why?
| | Phacoemulsification | 6 | 2025 | 123 | 2.130 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 1.550 |
Why?
| | Retinal Detachment | 2 | 2023 | 73 | 1.390 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 1.390 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 209 | 1.240 |
Why?
| | Intraoperative Complications | 4 | 2024 | 157 | 1.230 |
Why?
| | Blood Loss, Surgical | 2 | 2020 | 113 | 1.030 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.920 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 7 | 0.910 |
Why?
| | Ophthalmology | 2 | 2023 | 119 | 0.860 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.830 |
Why?
| | Optics and Photonics | 2 | 2021 | 37 | 0.810 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2022 | 6 | 0.750 |
Why?
| | Endothelium, Corneal | 1 | 2022 | 19 | 0.750 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.710 |
Why?
| | Lens Subluxation | 1 | 2021 | 4 | 0.670 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 80 | 0.660 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.660 |
Why?
| | Corneal Neovascularization | 1 | 2020 | 15 | 0.650 |
Why?
| | Retrospective Studies | 16 | 2025 | 17291 | 0.650 |
Why?
| | Corneal Stroma | 1 | 2020 | 24 | 0.640 |
Why?
| | Postoperative Complications | 6 | 2024 | 2970 | 0.640 |
Why?
| | Keratitis | 1 | 2020 | 20 | 0.640 |
Why?
| | Endophthalmitis | 1 | 2020 | 46 | 0.620 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5423 | 0.620 |
Why?
| | Eye Infections, Bacterial | 1 | 2020 | 45 | 0.620 |
Why?
| | Vitreous Body | 1 | 2020 | 117 | 0.610 |
Why?
| | Hepatitis C | 1 | 2022 | 256 | 0.600 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.570 |
Why?
| | Heroin Dependence | 1 | 2019 | 33 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2588 | 0.540 |
Why?
| | Conjunctival Neoplasms | 1 | 2017 | 7 | 0.520 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 19 | 0.510 |
Why?
| | Fingolimod Hydrochloride | 1 | 2017 | 40 | 0.500 |
Why?
| | Conjunctiva | 1 | 2017 | 52 | 0.500 |
Why?
| | Registries | 1 | 2025 | 2406 | 0.480 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 83 | 0.470 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8333 | 0.460 |
Why?
| | Anterior Chamber | 1 | 2015 | 26 | 0.460 |
Why?
| | Bacteria | 1 | 2020 | 765 | 0.430 |
Why?
| | Humans | 35 | 2026 | 145474 | 0.410 |
Why?
| | Cytoprotection | 1 | 2013 | 56 | 0.400 |
Why?
| | alpha-Crystallin B Chain | 1 | 2013 | 24 | 0.400 |
Why?
| | Thrombocytopenia | 1 | 2015 | 204 | 0.400 |
Why?
| | Internship and Residency | 2 | 2025 | 1267 | 0.390 |
Why?
| | Crystallins | 1 | 2013 | 61 | 0.380 |
Why?
| | Lens, Crystalline | 1 | 2013 | 136 | 0.350 |
Why?
| | Hot Temperature | 1 | 2013 | 396 | 0.320 |
Why?
| | Cornea | 2 | 2022 | 154 | 0.310 |
Why?
| | Aged | 11 | 2025 | 26153 | 0.310 |
Why?
| | Male | 19 | 2026 | 72842 | 0.300 |
Why?
| | Artificial Intelligence | 2 | 2025 | 381 | 0.290 |
Why?
| | Middle Aged | 11 | 2026 | 36215 | 0.270 |
Why?
| | Academic Medical Centers | 2 | 2022 | 554 | 0.270 |
Why?
| | Ophthalmologists | 2 | 2026 | 20 | 0.260 |
Why?
| | Oxidative Stress | 1 | 2013 | 1356 | 0.250 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3922 | 0.230 |
Why?
| | Clinical Competence | 2 | 2025 | 1243 | 0.230 |
Why?
| | Female | 14 | 2026 | 78844 | 0.230 |
Why?
| | Corneal Transplantation | 1 | 2025 | 17 | 0.230 |
Why?
| | Dry Eye Syndromes | 1 | 2026 | 56 | 0.220 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.210 |
Why?
| | Axial Length, Eye | 1 | 2024 | 16 | 0.210 |
Why?
| | United States | 6 | 2025 | 16098 | 0.210 |
Why?
| | Refractive Errors | 1 | 2024 | 36 | 0.200 |
Why?
| | Language | 2 | 2023 | 323 | 0.190 |
Why?
| | Descemet Membrane | 1 | 2022 | 7 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 363 | 0.190 |
Why?
| | Wet Macular Degeneration | 1 | 2023 | 58 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.180 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 238 | 0.180 |
Why?
| | Tissue and Organ Harvesting | 1 | 2022 | 78 | 0.180 |
Why?
| | Cell Count | 1 | 2022 | 319 | 0.180 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.180 |
Why?
| | Geographic Atrophy | 1 | 2023 | 97 | 0.180 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.170 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.170 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.170 |
Why?
| | Microscopy | 1 | 2022 | 147 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Hepacivirus | 1 | 2022 | 242 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.160 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1327 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Biometry | 1 | 2021 | 66 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2024 | 11772 | 0.160 |
Why?
| | Eye Injuries | 1 | 2021 | 53 | 0.160 |
Why?
| | Vitrectomy | 1 | 2020 | 73 | 0.160 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 8 | 0.150 |
Why?
| | Tattooing | 1 | 2020 | 12 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 321 | 0.150 |
Why?
| | Laser Therapy | 1 | 2021 | 144 | 0.150 |
Why?
| | Survival Rate | 1 | 2024 | 2090 | 0.150 |
Why?
| | HIV | 1 | 2020 | 251 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2020 | 101 | 0.150 |
Why?
| | Macular Edema | 1 | 2020 | 49 | 0.150 |
Why?
| | Tissue Donors | 1 | 2022 | 420 | 0.150 |
Why?
| | Arthritis, Reactive | 1 | 2019 | 7 | 0.150 |
Why?
| | Adult | 8 | 2025 | 40777 | 0.150 |
Why?
| | Dementia | 1 | 2023 | 327 | 0.140 |
Why?
| | Risk Factors | 2 | 2024 | 10885 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.140 |
Why?
| | Uveitis | 1 | 2020 | 149 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 562 | 0.130 |
Why?
| | Prosthesis Design | 1 | 2020 | 354 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.130 |
Why?
| | Biopsy | 2 | 2020 | 1082 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2026 | 1371 | 0.130 |
Why?
| | Epithelium, Corneal | 1 | 2017 | 41 | 0.120 |
Why?
| | Ultrasonography | 1 | 2020 | 785 | 0.120 |
Why?
| | Curriculum | 1 | 2023 | 1070 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2023 | 735 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1508 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2022 | 3623 | 0.100 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 31 | 0.100 |
Why?
| | Cell-Penetrating Peptides | 1 | 2013 | 21 | 0.100 |
Why?
| | Protein Structure, Quaternary | 1 | 2013 | 116 | 0.100 |
Why?
| | Blood Platelets | 1 | 2017 | 379 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 838 | 0.090 |
Why?
| | Cell Death | 1 | 2013 | 382 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2823 | 0.090 |
Why?
| | Cell Survival | 1 | 2013 | 1100 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1368 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1923 | 0.070 |
Why?
| | Young Adult | 2 | 2025 | 14218 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 552 | 0.070 |
Why?
| | Optometrists | 1 | 2026 | 12 | 0.060 |
Why?
| | Adolescent | 1 | 2025 | 22529 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 1987 | 181 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2008 | 235 | 0.050 |
Why?
| | Intubation, Intratracheal | 1 | 1987 | 325 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 217 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2026 | 5904 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2023 | 130 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 71 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 55 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 34 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 160 | 0.040 |
Why?
| | Health Surveys | 1 | 2021 | 518 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 609 | 0.030 |
Why?
| | Software | 1 | 2023 | 680 | 0.030 |
Why?
| | Cell Extracts | 1 | 2017 | 19 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2017 | 39 | 0.030 |
Why?
| | Mutation | 1 | 2008 | 4075 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2017 | 85 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 177 | 0.030 |
Why?
| | Cattle | 1 | 2017 | 946 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 355 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6066 | 0.020 |
Why?
| | Colorado | 1 | 2023 | 4553 | 0.020 |
Why?
| | Cell Movement | 1 | 2017 | 959 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1399 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2524 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7123 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2507 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2017 | 2046 | 0.020 |
Why?
| | TRPP Cation Channels | 1 | 2008 | 74 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 164 | 0.020 |
Why?
| | Rest | 1 | 1987 | 124 | 0.020 |
Why?
| | Physical Exertion | 1 | 1987 | 205 | 0.020 |
Why?
| | Genetic Testing | 1 | 2008 | 480 | 0.010 |
Why?
| | Hypoxia | 1 | 1987 | 1199 | 0.010 |
Why?
| | Animals | 1 | 2017 | 38030 | 0.010 |
Why?
|
|
Christopher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|